Truvada, produced by Gilead Sciences, offers the first HIV prevention pill. In the past, the official recommendation for HIV prevention was abstinence and condom use. The pill is marketed to young gay men, persons in a relationship with an HIV infected partner, and sex workers. From January 2011 to March 2013 more than 1,774 people have filled prescriptions for Truvada. This number does not include the several thousand who are in clinical trials for Truvada. Surprisingly, 50 percent of the prescriptions issued were for women. The rate of HIV infection is not slowing, with more than 50,000 new infections diagnosed per year. Men account for 50 percent of the newly diagnosed, with a high number of those being black men.